Deals in Depth: May 2008
Executive Summary
May 2008 dealmaking highlights: BMS stood out, getting a Phase II cardiovascular agent from KAI, selling off its ConvaTec wound healing division to private equity, and acquiring Kosan BioSciences; total private placement dollars in biopharma companies ($496mm) was almost half what it was in the previous month, while private investments in device players were up 67% to $278mm.
You may also be interested in...
Cosmetic And Personal Care Trademark Review 12 January, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
DBV Soars As Path For Peanut Allergy Patch Approval Clears
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
Need a specific report? 1000+ reports available
Buy Reports